In mammalian models, DGK competes with PKC for binding to DAG, thereby regulating PKC activity, and dysregulation of the PKC signalling pathway has been widely demonstrated in bipolar disorder patient populations and following therapeutic treatment (Sakai and Sakane, 2012; Saxena et al., 2017). Here, DGKE is linked to bipolar disorder.